Business Wire

Flirting with Fraud: Why Sextortion Is the Most Devastating Dating Scam

13.2.2025 14:00:00 CET | Business Wire | Press release

Share

Sextortion has emerged as one of the most dangerous forms of romance scams, preying on online daters and, tragically, claiming the lives of teenagers. Fraudsters use fake profiles to lure victims into sharing intimate content, only to threaten exposure unless a ransom is paid. Regula, a global developer of identity verification (IDV) solutions, shares a vision of how social media and dating platforms can strengthen protections to safeguard users.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250213790016/en/

Can you spot a romance scam? Scammers are getting smarter, using fake identities, AI, and emotional manipulation to exploit trust. See how these scams work and what can be done to stop them. (Graphic: Regula)

Romance scams come in many forms, exploiting trust and emotional vulnerability to defraud victims. Their common tactics include:

  • Catfishing: Scammers create fake identities to build trust and manipulate victims.
  • Military Scams: Fraudsters pose as deployed soldiers seeking financial assistance.
  • Inheritance Scams: Victims are deceived with false claims of large inheritances requiring upfront fees.
  • Pig-Butchering (Crypto Investment) Scams: Scammers feign romantic interest to lure victims into fraudulent investment schemes.

However, according to reports from leading child safety organizations, including the National Center for Missing and Exploited Children (NCMEC) and Thorn, sextortion is one of the most severe threats, with cases surging at an alarming rate. The FBI reported over 12,000 complaints in 2023 alone, resulting in millions in financial losses, severe psychological trauma, and, in some cases, even fatalities. Younger users and those new to online dating are particularly vulnerable.

Common sextortion tactics include:

  • Fake Identities: Scammers pose as attractive singles, influencers, or even celebrities to build quick trust.
  • Rapid Escalation: Conversations quickly shift from introductions to intimate exchanges.
  • Blackmail Threats: Once explicit content is shared, scammers demand money, cryptocurrency, or further compromising images under the threat of exposure.
  • AI-Driven Deception: Some scams leverage deepfake videos or AI-powered chatbots to manipulate victims.

The Role of Identity Verification in Preventing Sextortion

Sextortion thrives in environments where fake profiles and anonymity enable bad actors to operate freely. Social media and dating platforms play a critical role in combating this threat—through proactive moderation, AI-powered content monitoring, and user education. Stronger identity verification during registration is also a valuable tool in this arsenal, but it must be implemented thoughtfully, balancing fraud prevention with user privacy and accessibility.

Different online platforms use varying levels of verification, ranging from strongest to weakest:

  1. ID & Biometric Verification – Matching government-issued IDs with real-time selfies for authentication.
  2. Real-Time Selfies Without ID Validation – Confirming a live presence but without a verified identity document.
  3. Basic Checks – Verification through phone numbers, email, or linked social media accounts.
  4. Self-Reported Identity Without Validation – The least secure method, relying solely on user-provided information.

How Biometric and ID Verification Strengthens Security:

  • Eliminating Fake Profiles: Biometric checks make it significantly harder for scammers to create fake accounts.
  • Anti-Spoofing Technology: Prevents impersonation by detecting fraudulent attempts using photos or masks.
  • Liveness Detection: Confirms a real person is present, preventing AI-generated deception.

“When faced with strong verification measures, scammers don’t simply disappear—they move to less secure platforms where they can continue their schemes unchecked. Standardizing biometric ID verification across multiple platforms would make it significantly harder for them to do so, creating a safer ecosystem across social media, dating apps, and other online services." – Jan Stepnov, Identity Verification Expert at Regula.

Empowering Users to Stay Safe

While platforms must take stronger security measures, users can also protect themselves by:

  • Being Cautious of Fast-Moving Relationships: Avoid engaging in intimate exchanges early in conversations.
  • Interacting with Verified Users: Prioritize connections with verified profiles.
  • Reporting Suspicious Activity: Flagging blackmail attempts and scam behavior.
  • Never Paying Ransoms: Complying with extortion often leads to further threats.

For more insights on how identity verification is transforming online dating security, visit Regula’s blog.

About Regula

Regula is a global developer of forensic devices and identity verification solutions. With our 30+ years of experience in forensic research and the most comprehensive library of document templates in the world, we create breakthrough technologies for document and biometric verification. Our hardware and software solutions allow over 1,000 organizations and 80 border control authorities globally to provide top-notch client service without compromising safety, security, or speed. Regula has been repeatedly named a Representative Vendor in the Gartner® Market Guide for Identity Verification.

Learn more at www.regulaforensics.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20250213790016/en/

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Azafaros to Present at BIO International Convention 202615.6.2026 07:00:00 CEST | Press release

Azafaros, a private company building a portfolio to become a leader in lysosomal storage disorders (LSDs), focused on addressing neurological symptoms, today announced that it will present at the 2026 BIO International Convention taking place in San Diego, USA, from June 22-25. The company’s presentation is scheduled for Monday, June 22 at 4:30 PM in Theater 4. The presentation will highlight Azafaros’ progress in developing nizubaglustat, its lead investigational compound for the treatment of rare lysosomal storage disorders with neurological involvement, including GM1 and GM2 gangliosidoses (GM1/GM2) and Niemann-Pick type C disease (NPC). Nizubaglustat is currently in two Phase 3 registrational studies (NAVIGATE) treating patients with GM1/GM2 and NPC and expects to report topline data from the studies in 2028. “BIO provides an important opportunity to update our progress as we continue advancing nizubaglustat through late-stage clinical development,” said Stefano Portolano, CEO at A

Teledyne FLIR Defense Launches Black Recon™ Autonomous Micro-Drone15.6.2026 06:05:00 CEST | Press release

Autonomous launch, recovery, and recharge from military vehicles and fixed installations; Three-drone rotation provides persistent surveillance and real-time targeting data in contested environments Teledyne FLIR Defense, part of Teledyne Technologies Incorporated (NYSE: TDY), today announced at Eurosatory the market launch of Black Recon™, an autonomously launched micro-drone system that delivers continuous, untethered reconnaissance from military vehicles and fixed installations. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260614388428/en/ Teledyne FLIR Defense announced at Eurosatory the market launch of Black Recon™, an autonomously launched micro-drone that delivers continuous, untethered reconnaissance from military vehicles and fixed installations. Black Recon allows crews to launch, operate, recover, and recharge up to three UAS without leaving their platform, reducing operator risk. Designed for vehicle integrati

OM Pharma to Unveil the Largest Multi-Country Real-World Evidence Study on Broncho‑Vaxom® (OM‑85) for RTI Prevention at EAACI 202614.6.2026 10:00:00 CEST | Press release

REACH study met its first primary endpoint, showing that Broncho‑Vaxom® (OM‑85) was associated with a 28-38% reduction in respiratory tract infection rates at 12 months and 29-41% reduction at 24 months, comparing post-treatment versus pre-treatment initiation.1 The reduction was observed regardless of the frequency of respiratory tract infections in the previous year (1-3, >3) and across age subgroups (1-5, 6-11, 12-17, 18-64, >64 years).1 By reflecting everyday clinical practice and capturing episodes that necessitated a visit to the doctor, these extensive data offer critical new evidence of the therapy’s long-term relevance for patients suffering from recurrent respiratory tract infections. Evaluating a vast cohort of more than 15,790 paediatric, adolescent, adult and elderly patients in China, Italy, and Belgium, REACH represents the largest and only multi-country real-world evidence study to date for Broncho-Vaxom®.1,2 The study cohort includes patients with different co-morbidit

Incyte Announces New Positive Data at EHA 2026 Showed INCA033989 Achieved Rapid, Robust and Sustained Clinical and Molecular Responses and Was Well Tolerated in Patients with Myelofibrosis and Essential Thrombocythemia13.6.2026 17:15:00 CEST | Press release

In myelofibrosis (MF), INCA033989 delivered rapid and durable clinical benefits including meaningful spleen volume reductions, symptom improvement and anemia responses, both as a monotherapy and in combination with ruxolitinibIn essential thrombocythemia (ET), 87% of patients achieved a hematologic response, including 70% complete responses; responses were rapid (median ~2 weeks to a durable complete hematologic response) and durable (median response duration of 23 weeks)Across MF and ET, INCA033989 consistently reduced mutant CALR (mutCALR) variant allele frequency (VAF) in most evaluable patients, with reductions correlating with clinical responses and supporting its potential for disease modificationFirst-in-class mutCALR-targeted antibody shows potential to modify disease biology in both MF and ETINCA033989 demonstrated a favorable and manageable safety profile with no dose-limiting toxicities, with most patients with MF and ET continuing treatment Incyte (Nasdaq:INCY) today announ

Results from Incyte’s Pivotal Phase 3 frontMIND Trial of Tafasitamab (Monjuvi®/Minjuvi®) Combination Presented at the 2026 European Hematology Association (EHA) Congress Plenary Showed Prolonged Progression Free Survival13.6.2026 12:00:00 CEST | Press release

- frontMIND study evaluating tafasitamab (Monjuvi®/Minjuvi®) in patients with previously untreated high-risk diffuse large B-cell lymphoma (DLBCL) and high-grade B-cell lymphoma (HGBL) selected for the prestigious Plenary Abstracts Session at EHA 2026 - Results showed tafasitamab and lenalidomide plus R-CHOP (Tafa-Len-R-CHOP) significantly prolonged progression-free survival (PFS), reducing risk of disease progression or death by 25% - Positive trends toward PFS benefit with Tafa-Len-R-CHOP were observed acrossprespecified subgroups, including in patients with centrally confirmed lymphoma subtypes and both cell-of-origin (COO) molecular subtypes - The frontMIND data support global regulatory applications for tafasitamab and lenalidomide in addition to R-CHOP for previously untreated DLBCL and HGBL Incyte (Nasdaq:INCY) today announced positive results from the pivotal Phase 3 frontMIND trial evaluating the efficacy and safety of tafasitamab (Monjuvi®/Minjuvi®), a humanized Fc-modified c

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye